Pulmovant

Pulmovant is a clinical-stage biotechnology company developing treatments for pulmonary diseases. Its lead product candidate is mosliciguat, a potential first-in-class soluble guanylate cyclase (sGC) activator. The compound is designed as a once-daily, inhaled therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company is currently evaluating mosliciguat in the Phase 2 PHocus clinical trial, which is assessing the treatment's safety and efficacy. Pulmovant has received orphan drug designation for the compound in Japan, where it maintains a geographic presence.

Pulmovant operates within the Roivant family of companies, a model that emphasizes collaboration across its portfolio. The firm's work is concentrated in the biotechnology, pharmaceuticals, and pulmonary disease treatment sectors.